Lupin Share Price

    1943.9
    +4.70 (0.24%)
    LUPIN • 05 Sep, 2025 | 03:29 PM
    Buy
    with MTF at4.65xleverage

    1Y Annualised Return

    -12.55%

    3Y Annualised Return

    42.82%

    5Y Annualised Return

    15.76%

    10Y Annualised Return

    -0.06%

    The current prices are delayed, login or Open Demat Account for live prices.

    Lupin Stock Performance

    1W Return2.59
    1Y Return-15.12
    Today's Low1932
    Prev. Close1,939.20
    Mkt Cap (Cr.)88,788.51
    1M Return4.26
    3Y Return197.62
    52-Week High2402.9
    Open1,941.90
    PE Ratio16.84
    6M Return-3.29
    Today's High1970
    52-Week Low1795.2
    Face Value2

    Lupin Company background

    Founded in: 1983
    Managing director: Nilesh Deshbandhu Gupta.

    Lupin Limited is a top pharmaceutical company in India, globally recognized for its research and innovation orientation. It was established in 1968 by Dr. Desh Bandhu Gupta with a humble vision, which was to provide medicines at affordable prices to all and fulfill medical requirements that were not fulfilled. Lupin has become a worldwide giant over the years, manufacturing a broad array of drugs such as branded and generic medicines, biotechnology items, and essential ingredients used in the production of other drugs.

    A Global Pharmaceutical Powerhouse

    Lupin’s journey from a domestic-focused company to an internationally recognized pharmaceutical leader shows its relentless pursuit of excellence. The company operates in over 100 countries across North America, Europe, Asia-Pacific, and Africa. It’s headquartered in Mumbai, India. It has quite a strong presence in developed markets such as the United States, where it is among the top five generic pharmaceutical companies by prescriptions. Additionally, Lupin is a prominent player in emerging markets, catering to the healthcare needs of millions with high-quality and affordable medications.

    Innovation has been one of the most important cornerstones of Lupin's growth strategy. The company has invested significantly in research and development (R&D), establishing many state-of-the-art facilities across the world. These R&D centers focus greatly on creating complex generics, biosimilars, and specialty products, demonstrating Lupin’s commitment to advancing healthcare solutions. Lupin’s prowess in R&D has led to a robust pipeline of products that address quite a few therapeutic areas, including cardiovascular diseases, respiratory ailments, central nervous system disorders, diabetes, and oncology.

    Therapeutic Expertise

    Lupin's wide-ranging product portfolio covers a fairly substantial number of therapeutic areas. It holds a leadership position in anti-tuberculosis treatments, reflecting its dedication to combating global health challenges. Also, the company has made great strides in therapies for cardiovascular health, diabetes management, respiratory conditions, and women’s health. Lupin has managed to solidify its reputation as a trusted partner in the pharmaceutical industry by aligning its products with the needs of not only patients but also healthcare providers.

    Manufacturing Excellence

    Lupin's production facilities are among the strongest forces behind its success. The organization has numerous top-notch production facilities approved by top regulatory bodies like the US FDA, UK MHRA, and WHO. All these facilities have a fair number of state-of-the-art technologies to produce medicines of high quality. Lupin's focus on upholding high-quality standards reflects its commitment towards providing safe and effective pharmaceutical drugs to markets all around the world.

    Strategic Acquisitions and Partnerships

    Lupin has strategically expanded its reach and capabilities through acquisitions and partnerships. The acquisition of Gavis Pharmaceuticals and Novel Laboratories in the United States marked a great milestone in strengthening Lupin’s position in the world’s largest pharmaceutical market. The company’s partnerships with global pharmaceutical leaders have also enabled it to enhance its product offerings and cater to unmet medical needs.

    Commitment to Sustainability

    Other than its business activities, Lupin is greatly dedicated to corporate social responsibility and sustainable practices. Also, the firm is actively engaged in minimizing its environmental impact through green initiatives and optimal use of resources. Lupin's philanthropic organization, the Lupin Human Welfare and Research Foundation (LHWRF), has played a great role in empowering underprivileged society by focusing on healthcare, education, and skill development initiatives.

    Financial Performance and Market Presence

    Lupin has consistently delivered robust financial performance, driven by its diversified product portfolio, geographic expansion, and operational efficiency. The company’s ability to adapt to evolving market dynamics has also allowed it to maintain quite a competitive edge in the global pharmaceutical space. Investors often monitor Lupin share price as a barometer of the company’s market strength as well as its future prospects.

    Brief Overview

    While Lupin continues on its growth and innovation journey, it is always extremely committed to tackling new healthcare issues that emerge. The company is actively exploring new therapeutic areas, leveraging digital technologies, and enhancing its R&D capabilities to deliver breakthrough solutions. By staying true to its founding principles and embracing a forward-looking approach, Lupin aims to create a lasting impact on global healthcare.

    Lupin Limited’s story is one of resilience, innovation, and commitment to improving lives. From its humble beginnings to becoming a global pharmaceutical powerhouse, Lupin has consistently demonstrated its ability to adapt and thrive in a dynamic industry. With its unwavering focus on quality, sustainability, and patient-centric solutions, Lupin is well-positioned to lead the future of healthcare innovation.

    Lupin Financial Highlights


    Lupin reported a Q1 FY 2025-26 revenue of ₹6268.34 crore, up 13.8% YoY, with net profit increased 70.8% to ₹1221.46 crore. For the full year FY2025–2026, revenue reached ₹22903.72 crore and profit touched at ₹3306.26 crore. As of Jun '25, Lupin’s market capitalisation stood at ₹88,788.51 crores. Shareholding as of Jun '25 shows promoters holding 46.9%, with FIIs at 21.2%, DIIs at 25.6%, and public at 6.3%.

    As of 6 Sep, 2025, Lupin share price is ₹1943.9. The stock opened at ₹1941.9 and had closed at ₹1939.2 the previous day. During today’s trading session, Lupin share price moved between ₹1,932.00 and ₹1,970.00, with an average price for the day of ₹1951.00. Over the last 52 weeks, the stock has recorded a low of ₹1,795.20 and a high of ₹2,402.90. In terms of performance, Lupin share price has declined by 0.5% over the past six months and has declined by 12.55% over the last year.
    Read More
    Lupin SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹61,07,100 (-6.04%)
    Daily SIP of 25,000 would have become 61,07,100 in 1 year with a gain of -3,92,899 (-6.04%)
    View details of Market Depth

    Lupin Fundamental

    Market Cap (in crs)

    88,788.51

    Face Value

    2

    Turnover (in lacs)

    6,219.68

    Key Metrics

    Qtr Change %
    0
    Dividend yield 1yr %
    Below industry Median
    0.6

    Lupin Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Lupin Quarterly Revenue
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    6268.34 Cr
    5667.13 Cr
    5767.71 Cr
    5672.73 Cr
    5600.33 Cr
    Lupin Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    22903.72 Cr
    20130.99 Cr
    16715.02 Cr
    16547.17 Cr
    15299.25 Cr
    15858.52 Cr
    Lupin Quarterly Net Profit/Loss
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    1221.46 Cr
    782.38 Cr
    858.86 Cr
    859.48 Cr
    805.54 Cr
    Lupin Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    3306.26 Cr
    1935.57 Cr
    447.69 Cr
    -1509.72 Cr
    1226.6 Cr
    -403.82 Cr

    Lupin Result Highlights

    • Lupin Ltd reported a 27.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 12.0%.

    • Its expenses for the quarter were up by 9.8% QoQ and 5.5% YoY.

    • The net profit increased 231.7% QoQ and increased 51.6% YoY.

    • The earnings per share (EPS) of Lupin Ltd stood at 26.6 during Q1 FY 2025-26.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Lupin Shareholding Pattern

    Promoter
    46.9%
    Foreign Institutions
    21.2%
    Mutual Funds
    19.4%
    Domestic Institutions
    25.6%
    Public
    6.3%
    Promoter
    46.9%
    Foreign Institutions
    21.5%
    Mutual Funds
    17.6%
    Domestic Institutions
    25.4%
    Public
    6.2%
    Promoter
    47%
    Foreign Institutions
    22%
    Mutual Funds
    16.9%
    Domestic Institutions
    24.8%
    Public
    6.3%
    Promoter
    47%
    Foreign Institutions
    21.5%
    Mutual Funds
    16.9%
    Domestic Institutions
    25.1%
    Public
    6.4%
    Promoter
    47%
    Foreign Institutions
    19.3%
    Mutual Funds
    16.2%
    Domestic Institutions
    26.8%
    Public
    6.9%
    Promoter
    47%
    Foreign Institutions
    18.3%
    Mutual Funds
    16.8%
    Domestic Institutions
    27.8%
    Public
    6.9%

    Lupin Technical Analysis

    Moving Averages Analysis
    1943.9
    Current Price
    Bullish Moving Averages
    11
    Bearish Moving Averages
    5
    5Day EMA
    1,932.60
    10Day EMA
    1,931.10
    12Day EMA
    1,931.60
    20Day EMA
    1,933.10
    26Day EMA
    1,934.20
    50Day EMA
    1,942.10
    100Day EMA
    1,964.90
    200Day EMA
    1,969.90
    5Day SMA
    1,924.40
    10Day SMA
    1,928.50
    20Day SMA
    1,941.30
    30Day SMA
    1,934.80
    50Day SMA
    1,935.10
    100Day SMA
    1,970.60
    150Day SMA
    1,987.50
    200Day SMA
    2,027.50
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    129117 Rs
    345214 Rs
    Week Rs
    211089 Rs
    452653 Rs
    Month Rs
    475115 Rs
    910116 Rs
    1,948.63
    Pivot
    Resistance
    First Resistance
    1,965.27
    Second Resistance
    1,986.63
    Third Resistance
    2,003.27
    Support
    First Support
    1,927.27
    Second support
    1,910.63
    Third Support
    1,889.27
    Relative Strength Index
    51.77
    Money Flow Index
    43.75
    MACD
    -2.64
    MACD Signal
    -2.53
    Average True Range
    41.60
    Average Directional Index
    12.80
    Rate of Change (21)
    4.26
    Rate of Change (125)
    -0.48
    Name
    Holding Percent
    Hdfc Trustee Company Ltd. A/C Hdfc Balanced Advantage Fund
    3.78
    Icici Prudential Value Discovery Fund
    3.22
    Nippon Life India Trustee Ltd-A/C Nippon India Growth Fund
    2.1
    Sbi Long Term Equity Fund
    1.72
    Mirae Asset Large & Midcap Fund
    1.52
    Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Midcap Fund
    1.29
    Hdfc Life Insurance Company Limited
    1.31
    Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I
    1.48

    Lupin Latest News

    03 SEP 2025 | Wednesday

    Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension

    03 SEP 2025 | Wednesday

    Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    03 SEP 2025 | Wednesday

    Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    View More

    Lupin Share Price FAQs

    Lupin share price is ₹1943.9 in NSE and ₹1944.65 in BSE as on 5/9/2025.

    Lupin share price in the past 1-year return was -15.12. The Lupin share hit a 1-year low of Rs. 1795.2 and a 1-year high of Rs. 2402.9.

    The market cap of Lupin is Rs. 88788.51 Cr. as of 5/9/2025.

    The PE ratios of Lupin is 16.84 as of 5/9/2025.

    The PB ratios of Lupin is 3.65 as of 5/9/2025

    The Mutual Fund Shareholding in Lupin was 19.35% at the end of 5/9/2025.

    You can easily buy Lupin shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Lupin share price is ₹2402.9 and ₹1795.2 as of 5/9/2025.

    The earnings per share (EPS) of Lupin stood at 26.6 during Q1 FY 2025-26.

    Please be aware that Lupin stock prices are subject to continuous fluctuations due to various factors.

    Open Demat Account
    +91 -

    Popular Stocks
    57.87
    +0.45 (+0.78%)
    123.46
    +1.83 (+1.50%)
    691.70
    +4.20 (+0.61%)
    2,281.40
    +2.60 (+0.11%)
    145.51
    +1.50 (+1.04%)
    329.40
    +2.45 (+0.75%)
    167.68
    +0.87 (+0.52%)
    329.15
    +2.90 (+0.89%)
    370.80
    -1.70 (-0.46%)
    385.80
    +3.20 (+0.84%)
    Top Gainers
    6,580.50
    +155.50 (+2.42%)
    3,561.30
    +79.80 (+2.29%)
    14,895.00
    +233.00 (+1.59%)
    285.35
    +3.55 (+1.26%)
    1,268.10
    +15.10 (+1.21%)
    Top Losers
    407.35
    -8.55 (-2.06%)
    1,419.00
    -24.30 (-1.68%)
    1,553.40
    -24.40 (-1.55%)
    3,048.30
    -47.40 (-1.53%)
    1,477.90
    -22.50 (-1.50%)
    Open Demat Account
    +91 -